Lanarif

Quick links to important sections

Lanarif

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lanarif

Quick Facts

Property Description
Active ingredient Rifampicin (INN)
Forms Capsule, Tablet, Intravenous Solution
Pharmacological class Rifamycin Antibiotic
General purpose Anti-infective / Bacterial elimination
Origin Semisynthetic

Defining Lanarif: A Rifamycin Antibiotic

Lanarif is a trade name for a pharmaceutical preparation whose active ingredient is Rifampicin (INN), a potent agent classified pharmacologically as a Rifamycin class antibiotic and specialized anti-tuberculosis agent. It is fundamentally an anti-infective used to target and eliminate persistent bacterial pathogens. The compound Rifampicin is widely recognized as essential in public health efforts and is a core component of treatment protocols globally.

Composition, Origin, and Available Forms

Lanarif is a Single-ingredient product derived from a natural source: it is defined as a Semisynthetic compound originating from a fermentation product of the bacterium Amycolatopsis rifamycinica. This means the substance combines a natural base with chemical modification to enhance its therapeutic properties. The drug is formulated for flexible patient care and administration, being available in multiple Dosage form(s) including oral Capsules or Tablets, and a sterile Intravenous solution for parenteral use. Lanarif's distinct positioning is tied to its status as a prescription-only medication specifically utilized in complex, long-term anti-infective management.

The Core Mechanism and General Anti-Infective Purpose

The general purpose of Lanarif is to achieve the rapid destruction of invading bacteria, relying on a potent bactericidal activity that acts directly against the pathogen. Its specialized mechanism involves the swift disruption of the bacteria’s internal machinery, essentially blocking the production of genetic material (RNA) required for the pathogen to survive and reproduce. This targeted process prevents the bacteria from replicating and ensures their elimination, positioning Lanarif as a reliable agent for bringing challenging bacterial infections under decisive control.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Lanarif?

Possible Side Effects and Safety Information

Regulatory documents classify the potential adverse reactions of Lanarif (Rifampicin) across a spectrum of frequency and physiological systems. This information establishes the official safety profile for the medicine.

Frequency-Classified Adverse Reactions

  • Very Common: The expected, non-pathological consequence of treatment is the reddish-orange or brown discoloration of body fluids, including urine, tears, sweat, and saliva. Patients should note that this effect may permanently stain soft contact lenses.
  • Common: Adverse reactions listed as common typically include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort. Neurological effects such as headache, fatigue, and dizziness, along with transient elevations in liver enzymes (transaminases), are also frequently observed.

System-Organ Class Effects and Serious Reactions

The medicine is officially documented to affect several key organ systems. Adverse reactions involving the Hepatobiliary System (liver) can range from transient enzyme abnormalities to hepatitis and, in rare cases, fatal hepatotoxicity. Effects on the Blood and Lymphatic System include thrombocytopenia (low platelet count) and hemolytic anemia.

Serious, but uncommon, adverse reactions explicitly documented in official labeling include Acute Renal Failure and severe immunological responses, such as the flu-like syndrome. The official safety profile also identifies Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety Constraints and Exposure Patterns

The use of Lanarif is contraindicated in individuals with a history of hypersensitivity to any drug in the rifamycin class or those with severe acute liver disease. The safety profile notes that immunologically mediated reactions, such as the flu-like syndrome, are more frequently reported with intermittent dosing schedules compared to daily administration. Furthermore, specific safety considerations exist for individuals with pre-existing hepatic impairment due to the increased risk of hepatotoxicity.

Overdose and Emergency Response

Lanarif overdose information is derived from official regulatory and toxicological documentation. Manifestations of acute overdose often include distinct systemic discoloration, appearing as a brownish-red or orange hue in the skin, urine, sweat, saliva, tears, and feces (chromaturia). This is typically accompanied by common gastrointestinal symptoms such as nausea, vomiting, and abdominal pain.

The severity of overdose is characterized by documented risks to vital organ systems. Severe outcomes include signs of hepatotoxicity, which can progress to acute liver failure, and nephrotoxicity, leading to acute kidney injury or renal dysfunction. Central nervous system involvement is noted, presenting as altered sensorium, unconsciousness, and tonic-clonic convulsions. Life-threatening complications also involve severe metabolic acidosis and hypotension.

Due to the potential for fatal poisoning and severe organ damage, regulatory guidance mandates that individuals seek immediate medical attention for any suspected overdose. The official prescribing information states that no specific antidote is known for Rifampicin; therefore, clinical management relies exclusively on intensive symptomatic and supportive measures, including hospital monitoring. Individuals with pre-existing severe hepatic disease face a significantly higher risk of a poor prognosis following overdose.

Therapeutic Uses of Lanarif

What Lanarif Treats: Main Uses and Benefits

Lanarif (Rifampicin) is an anti-infective generally applied in contexts involving heightened systemic burden where therapeutic action against specific, persistent bacterial pathogens is required. Its therapeutic scope generally includes two primary domains: long-term disease management and crucial short-term prevention.


Therapeutic Scope and Core Benefit

This medication is commonly used as a core component in therapeutic regimens for chronic mycobacterial diseases, including Tuberculosis (TB) and Leprosy, and is relevant for managing serious, persistent bacterial infections of deep tissues. It is also often applied when post-exposure prophylaxis is appropriate, such as following close contact with pathogens causing Meningococcal disease or Haemophilus influenzae type b (Hib).

Lanarif is relevant in conditions presenting with systemic or localized discomfort, such as persistent fevers, night sweats, and chronic fatigue, to assist with symptom management. This use provides support that helps ease the overall symptom burden that interferes with long-term stability and functioning.

“This approach is relevant when supportive symptom management is appropriate in currently asymptomatic individuals who are at heightened risk of developing a severe infection.”

Quick Fact: Relief for Constitutional Symptoms
This medicine is commonly used to help manage symptoms related to systemic imbalance, particularly those associated with chronic infection, such as fever, fatigue, and night sweats. It contributes to easing the overall symptom load during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility for Lanarif (Rifampicin): Official Regulatory Rules

Lanarif is generally approved for use across all age ranges, but its eligibility is strictly defined by regulatory contraindications and physiological status, primarily concerning liver function and reproductive health.

Category Official Regulatory Status
Populations for whom use is allowed Adults, Older Adults, and Pediatric patients (including neonates, infants, and children). No dose adjustment is required for renal impairment.
Populations for whom use is contraindicated Patients with a history of hypersensitivity to any drug in the rifamycin class (e.g., rifampicin, rifapentine, rifabutin). Patients with active liver disease or current jaundice.
Eligibility-related restrictions Use is restricted in cases of pre-existing, stable hepatic impairment, requiring close monitoring. It is also contraindicated if the patient is taking specific concomitant antiviral agents (e.g., lurasidone).
Pregnancy and lactation eligibility status Restricted. Use during pregnancy is permitted only if the benefit justifies the risk to the fetus. The label advises a decision to discontinue nursing or discontinue the drug while breastfeeding, as the medicine is excreted into human milk.

The regulatory profile prohibits the use of Lanarif in patients with active liver disease or an allergy to rifamycins. For all other approved populations, including children of all ages, use is established, provided conditional restrictions—such as those related to pre-existing hepatic impairment or pregnancy—are observed as defined in official government prescribing documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lanarif (Rifampicin) has officially documented interaction patterns that are primarily driven by its effect as a strong inducer of metabolic enzymes and transport systems.

Documented Interaction Profiles

Classification
Enzyme System and Transporter Induction
Formal Prohibitions
Exposure Reduction
Timing and Absorption Restrictions
Additive Organ Toxicity Risk

Officially Documented Restrictions

Lanarif is contraindicated for co-administration with several agents, including Lurasidone, Ritonavir-boosted Saquinavir, and specific antivirals such as Bictegravir. These combinations are prohibited due to the risk of severe toxicity or the substantial decrease in the co-administered drug's plasma concentration.

As a potent inducer of the CYP450 enzyme system and the P-glycoprotein system, Lanarif accelerates the elimination of many medicines, leading to reduced exposure and efficacy of drugs like oral hormonal contraceptives, corticosteroids, and certain anticoagulants.

Interaction with food results in a reduction of Lanarif's absorption by approximately 30%. Furthermore, administration with p-aminosalicylic acid (PAS) requires the drugs to be given at least 4 hours apart to maintain adequate Lanarif serum levels. Concomitant use with Isoniazid or routine alcohol consumption significantly increases the potential for hepatotoxicity, a pharmacodynamic effect officially noted in product labeling. The drug must not be used in patients with severe hepatic disease.

Mechanism of Action

How Lanarif Works

Lanarif's mechanism of action is defined by a primary, highly selective mechanism targeting bacterial components and a separate, secondary interaction with the host body's metabolic pathways. The following explains these core pharmacodynamic domains and their resulting physiological consequences.


Direct Inhibition of Bacterial Genetic Machinery

Lanarif (Rifampicin) works by selectively binding to the bacterial enzyme, DNA-dependent RNA Polymerase (RNAP), specifically targeting the beta-subunit. This interaction creates a steric occlusion that physically blocks the enzyme from continuing the transcription process, immediately stopping the synthesis of new RNA strands. This molecular interference causes a bactericidal effect, resulting in the killing of the bacterial cells due to the cessation of essential protein synthesis.


Host-Level Modulation of Metabolic Enzymes

Separately from its primary mechanism, Lanarif functions as an agonist of the human Pregnane X Receptor (PXR), a nuclear receptor that regulates metabolic enzyme expression. This mechanism upregulates the production of key Cytochrome P450 (CYP) enzymes in the liver and gut. The resulting physiological effect is the accelerated clearance and removal of various compounds from the body, a secondary consequence of accelerated clearance for substrates of the induced enzymes.

Dosage and Administration Information

How Lanarif is Used: Administration Guidelines

Lanarif (Rifampicin) is administered based on guidelines that define its use primarily as a component of combination therapy over specific durations. Its usage is highly structured around its approved routes, precise dosing, and scheduling rules.


Administration and Dosage Regimens

Administration is either Oral (capsules/tablets) or Intravenous (IV) solution, with the IV route typically reserved for acutely ill patients unable to take oral forms. Oral dosage is critically time-dependent, as it must be taken in a fasted state—either 1 hour before or 2 hours after a meal to maximize absorption.

Usage Context Standard Adult Dosing (Max.) Administration Frequency
Tuberculosis Treatment 10 mg/kg up to 600 mg daily Once Daily
Meningococcal Prophylaxis 600 mg Twice Daily (BID)
Other Severe Infections 600 mg to 1200 mg total daily dose In 2 to 4 divided doses

Procedural Context and Duration

For active infections, Lanarif is used in combination with at least one other anti-infective agent to prevent the rapid development of bacterial resistance. Treatment durations for conditions like active tuberculosis often span six months or longer as part of a sustained regimen, while prophylaxis regimens are typically short-term (2-4 days).

Special Population Rules: Pediatric dosing is weight-based (10 to 20 mg/kg/day) without exceeding the 600 mg adult maximum. Dose adjustments are required for patients with hepatic impairment, with the daily dose not exceeding 8 mg/kg body weight.

Missed Dosing: If a dose is missed, it should be taken as soon as remembered, but the instruction is to never take a double dose to make up for a forgotten one.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lanarif

Evidence for Use in Tuberculosis (TB) Treatment

The use of Lanarif was evaluated in the treatment of Tuberculosis (TB) in multiple studies. This includes Randomized Controlled Trials (RCTs) and Systematic Reviews that synthesize the data. Researchers studied outcomes related to the elimination of the pathogen, such as the rate of bacterial clearance and the frequency of disease recurrence. Findings indicate that the full course of therapy including Lanarif was associated with specific measurements of treatment success and recurrence rates when the regimen was completed.

Current research has explored modifications to the standard regimen. Recent Dose-Ranging Trials have been conducted to examine if higher-than-standard doses of Lanarif could potentially be part of a shorter overall treatment course. The long-term evidence needed to establish if higher doses are linked to different overall treatment success measurements is still emerging.

Evidence for Use in Exposure to Infection

Lanarif has also been studied for its use following exposure to certain bacterial infections.

For Leprosy exposure, Cluster Randomized Studies examined a single dose of Lanarif in household and social contacts. Findings describe patterns observed where a single dose was associated with specific measurements of incidence among contacts over the intermediate-term follow-up period.

For exposure to pathogens like those causing Meningococcal disease and Haemophilus influenzae type b, studies examined clearance of the carrier state. This evidence informs the views of regulatory bodies. Some comparative research describes a pattern where the drug's use in this context was associated with the subsequent detection of drug-resistant isolates in the community.

Research Gaps and Uncertainties

While the established use of Lanarif is well-documented, certain gaps remain. Data are still emerging for investigational regimens using higher doses, and the overall certainty remains low regarding their ability to modify treatment time. Long-term effects are not fully established for these novel approaches. Furthermore, comparative evidence is lacking between Lanarif and some newer agents for certain uses, making it harder to synthesize all available evidence.

Key Studies & References

  1. WHO Model List of Essential Medicines – Rifampicin (Rifampin)

Frequently Asked Questions (FAQ)

Common questions about Lanarif (FAQ)


Q: Do people typically experience weight gain or weight loss while taking Lanarif?

Regulatory documents indicate that Lanarif can cause various gastrointestinal issues. While weight loss is listed as a possible symptom of concern in some official documentation, neither significant weight gain nor weight loss are consistently listed as common or very common side effects experienced by most patients.


Q: How long does it usually take for Lanarif to start working?

Lanarif’s active ingredient is rapidly absorbed by the body. Once absorbed, it begins its work by targeting and destroying bacteria (bactericidal activity). However, the time it takes for a person to notice clinical improvement is not precisely defined in official product information.


Q: What is the expected duration of the treatment course with Lanarif?

The required duration of Lanarif treatment varies significantly based on the specific infection being treated. Treatment for active infections like tuberculosis often requires a sustained regimen lasting six months or more as part of a combination therapy, based on official prescribing information. In contrast, using the drug for prophylaxis (preventive treatment) may only be for a short-term period.


Q: Can I take pain relievers like ibuprofen or acetaminophen with Lanarif?

Lanarif is a strong enzyme inducer, which can cause the effectiveness of many different medicines to be reduced. Furthermore, official warnings note a potential additive risk of hepatotoxicity (liver damage) when Lanarif is used with other potentially liver-toxic agents, which may include acetaminophen.


Q: Are there any vitamins or supplements that interact with Lanarif?

Because Lanarif is a strong inducer of liver enzymes, it can reduce the levels and effectiveness of various other compounds. Official labeling notes interference with laboratory tests for Vitamin B12 and folate. Official warnings note potential interactions with certain herbal supplements, such as St. John’s wort, due to the drug’s metabolic effects.


Q: Does Lanarif interact with alcohol?

Yes, regulatory documents clearly state that co-use of routine alcohol consumption and Lanarif is associated with a severe risk of hepatotoxicity (liver damage). Patients are advised that this combination is cautioned against in official prescribing information.


Q: Does Lanarif affect sleep patterns?

Common side effects of Lanarif include neurological effects such as headache and fatigue. While insomnia is not typically listed as a common effect, some rare neurological or psychiatric side effects, such as confusion or psychoses, have been documented in official reports, which could potentially affect sleep.


Q: What happens when you stop taking Lanarif?

Regulatory guidance emphasizes the need to complete the full course of therapy as prescribed. Stopping the drug prematurely can lead to the rapid development of drug-resistant bacteria and treatment failure. Immunological reactions like the 'flu-like syndrome' are also more frequently reported after a lapse in therapy.


Q: Is Lanarif known to cause headaches?

Yes, official product information lists headache as a common neurological adverse reaction. Patients who experience severe or persistent headaches are advised to consult their healthcare provider for guidance.


Q: How often do people need to take Lanarif?

The administration frequency for Lanarif is highly dependent on the specific infection or condition being treated and the overall treatment regimen. Frequency varies, as it is used daily in some cases and less often in others.


Q: Does Lanarif have a reputation for being effective?

The active ingredient in Lanarif is included on the World Health Organization (WHO) Essential Medicines List. This inclusion, supported by extensive research, highlights its importance and role as a core component of established anti-infective treatment protocols globally.


Q: Does Lanarif interact with birth control pills?

Yes, this is a significant interaction. Lanarif is a powerful enzyme inducer that drastically reduces the concentration and efficacy of oral hormonal contraceptives. The interaction can lead to a risk of contraceptive failure, and this information is highlighted in the official prescribing documentation.


Q: Does the effectiveness of Lanarif change over time?

The effectiveness of Lanarif can change for two main reasons. First, the drug can cause self-induction of its own metabolism, leading to a decreased blood half-life with repeated daily use. Second, the development of bacterial resistance can occur rapidly if Lanarif is used alone, which reduces its long-term effectiveness against the infection.


Q: What are the common reasons patients stop taking Lanarif?

The most common reason for stopping Lanarif is the completion of the required multi-month treatment regimen. Other frequent reasons include the onset of intolerable adverse effects like gastrointestinal issues, or more serious events such as elevated liver enzymes or hypersensitivity reactions, which may require discontinuation.


Q: What are the common misunderstandings about how Lanarif should be used?

Common misunderstandings often relate to administration rules. For instance, the drug is intended to be taken on an empty stomach to maximize absorption. Official guidance warns against taking a double dose to compensate for a missed one, and Lanarif is typically prescribed as part of a combination therapy to help prevent bacterial resistance.


Q: Can Lanarif cause mood changes or anxiety?

Common side effects include neurological symptoms like dizziness and fatigue. While severe psychiatric effects are considered rare, post-marketing reports have documented effects such as mental depression, confusion, and psychoses, which fall under the category of mood or mental changes.


Q: Do people typically experience reddish-orange or brown discoloration of body fluids while taking Lanarif?

Yes, this is a very common and expected effect of taking Lanarif. It causes a reddish-orange or brown discoloration of body fluids, including urine, tears, sweat, and saliva. This effect is non-pathological, but patients who wear soft contact lenses should be aware that the lenses may become permanently stained.


Q: Is there a generic version of Lanarif available?

Yes, the active ingredient in Lanarif, known as rifampicin (or rifampin), is a well-established medicine. The active drug substance is widely available in generic form.


Q: Will Lanarif affect my ability to drive or operate machinery?

Lanarif may cause common side effects such as headache, dizziness, and fatigue. Official guidance advises patients to use caution until they are certain how the medication affects them, as these effects could potentially impair the ability to drive or operate machinery.


Q: What is the storage recommendation for Lanarif?

Official guidance specifies that Lanarif should be stored at a Controlled Room Temperature (20°C to 25°C). To maintain the drug’s stability, it requires being kept in its original container with the lid tightly closed and protected from light.


Q: Where can I find official patient information leaflets about Lanarif?

Official patient information can be found in the Patient Information Leaflet (PIL) that is dispensed with the medication. This information is also available online via government regulatory sites such as the FDA DailyMed or the EMA SmPC, which contain the full, authorized patient instructions.


Q: What are the key safety warnings associated with Lanarif?

Key regulatory warnings emphasize the risk of hepatotoxicity (severe liver injury), and the potential for severe, life-threatening immunological reactions and skin reactions (like Stevens-Johnson Syndrome). There are also critical warnings about potential severe drug interactions due to its potent enzyme induction.


Q: Is Lanarif safe to use for elderly patients?

Use of Lanarif is generally allowed for adults and older adults. However, official guidance advises that caution should be exercised in elderly patients, particularly if there are signs of impaired liver function. Dose adjustments are sometimes required by healthcare providers in such cases.


Q: Is Lanarif a controlled substance?

No, Lanarif’s active ingredient, rifampicin, is an anti-infective medication. It is a prescription-only drug but is not classified as a controlled substance under the US Controlled Substances Act (CSA) or similar international scheduling systems.


Q: Can Lanarif be crushed or split if I have trouble swallowing pills?

Regulatory guidance concerning crushing or splitting varies by the specific formulation (capsule vs. tablet) and manufacturer. This action is only advised if the specific formulation prescribed is explicitly authorized for modification, as per official guidance.

How should Lanarif be stored and disposed of?

Storage Requirements

Lanarif (Rifampicin) must be stored at Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F), with permissible temperature excursions up to 30 C. The medicine must be kept in its original container with the lid tightly closed and requires protection from light to maintain stability.

Stability and Handling

For the intravenous solution, the reconstituted mixture must not be stored below 15 C to avoid precipitation and should be used within 24 hours.

Disposal and Child Safety

All forms of Lanarif must be stored out of the sight and reach of children. Unused or expired medication should not be disposed of in household waste or wastewater, as per regulatory instructions. Proper disposal requires consulting a pharmacist or utilizing an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lanarif found in:

A-Z Index: